Clinical Trial Update: Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose) [Phase 1]

View source ↗

Summary

Phase 1 study of NGP-555 in healthy volunteers completed, examining 14-day multiple ascending doses for Alzheimer's disease-related research.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• NGP 555

Snippet

Sponsor: NeuroGenetic Pharmaceuticals Inc | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED